NCT01748890

Brief Summary

Prostate cancer is the most common cancer and the second-leading cause of cancer death amongst men in the United States. Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness. It permits measurement of the elastic properties of tissue. These measurements can be transposed onto conventional anatomic ultrasound images, producing a colorized overlay that allows direct visualization of the anatomic distribution of tissue stiffness. In this study, we aim to determine whether prostate biopsies planned with sonoelastographic guidance would be more likely than random prostate biopsies to intersect with foci of carcinoma in the prostate gland, and to determine whether prostate biopsies planned with sonoelastographic guidance would be more likely than random prostate biopsies to yield histopathology representative of the final Gleason Score obtained at pathologic assessment of the resected prostate.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable prostate-cancer

Timeline
Completed

Started Dec 2009

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

December 1, 2009

Completed
2.9 years until next milestone

First Submitted

Initial submission to the registry

October 31, 2012

Completed
1 month until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2012

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2012

Completed
12 days until next milestone

First Posted

Study publicly available on registry

December 13, 2012

Completed
1.4 years until next milestone

Results Posted

Study results publicly available

May 20, 2014

Completed
Last Updated

October 20, 2017

Status Verified

October 1, 2017

Enrollment Period

3 years

First QC Date

October 31, 2012

Results QC Date

April 17, 2014

Last Update Submit

October 19, 2017

Conditions

Outcome Measures

Primary Outcomes (1)

  • The Number of Core Biopsies in These Targeted Regions

    From elastography-prostatectomy pathology correlation, the following data will be obtained, 1) The number of planned core biopsies that would intersect foci of prostate carcinoma, 2) The Gleason Score that would be obtained, assuming that elastographically targeted biopsies sample the targeted region.

    Participants will be followed until prostatectomy pathology is available (average 1 week)

Study Arms (1)

Sonoelastography

EXPERIMENTAL

Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.

Device: Sonoelastography

Interventions

Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.

Also known as: Hitachi, HI VISION Preirus
Sonoelastography

Eligibility Criteria

Age18 Years+
Sexmale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age 18 years of age or older.
  • Serum PSA between 4 and 10 ng/mL.
  • A diagnosis of prostate cancer based on extended (twelve core) random prostate biopsy within three months prior to study entry.
  • Clinically localized prostate carcinoma i.e. TNM stage T2c or less.
  • The patient has elected to undergo radical prostatectomy to treat the prostate carcinoma.
  • The patient consents to undergo a diagnostic transrectal ultrasound of the prostate with elastography.

You may not qualify if:

  • \. Any contraindication to transrectal ultrasonography, including prior anorectal surgery, inflammatory bowel disease, rectal fistula, or fissure-in-ano.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Massachusetts General Hospital

Boston, Massachusetts, 02114, United States

Location

MeSH Terms

Conditions

Prostatic Neoplasms

Interventions

Elasticity Imaging Techniques

Condition Hierarchy (Ancestors)

Genital Neoplasms, MaleUrogenital NeoplasmsNeoplasms by SiteNeoplasmsGenital Diseases, MaleGenital DiseasesUrogenital DiseasesProstatic DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

UltrasonographyDiagnostic ImagingDiagnostic Techniques and ProceduresDiagnosis

Results Point of Contact

Title
Anthony E. Samir
Organization
Massachusetts General Hospital

Study Officials

  • Anthony E. Samir, MD

    Massachusetts General Hospital

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
Yes

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Radiologist, Ultrasound Imaging Services Assistant Radiologist, Abdominal Imaging & Intervention

Study Record Dates

First Submitted

October 31, 2012

First Posted

December 13, 2012

Study Start

December 1, 2009

Primary Completion

December 1, 2012

Study Completion

December 1, 2012

Last Updated

October 20, 2017

Results First Posted

May 20, 2014

Record last verified: 2017-10

Locations